These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 22292133)
1. Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma. Dumaz N Small GTPases; 2011 Sep; 2(5):289-292. PubMed ID: 22292133 [TBL] [Abstract][Full Text] [Related]
2. ERK and PDE4 cooperate to induce RAF isoform switching in melanoma. Marquette A; André J; Bagot M; Bensussan A; Dumaz N Nat Struct Mol Biol; 2011 May; 18(5):584-91. PubMed ID: 21478863 [TBL] [Abstract][Full Text] [Related]
3. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Dumaz N; Hayward R; Martin J; Ogilvie L; Hedley D; Curtin JA; Bastian BC; Springer C; Marais R Cancer Res; 2006 Oct; 66(19):9483-91. PubMed ID: 17018604 [TBL] [Abstract][Full Text] [Related]
4. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells. Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656 [TBL] [Abstract][Full Text] [Related]
5. Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of CRAF and MEK1/2. Wang P; Jia X; Lu B; Huang H; Liu J; Liu X; Wu Q; Hu Y; Li P; Wei H; Liu T; Zhao D; Zhang L; Tian X; Jiang Y; Qiao Y; Nie W; Ma X; Bai R; Peng C; Dong Z; Liu K Signal Transduct Target Ther; 2023 Mar; 8(1):96. PubMed ID: 36872366 [TBL] [Abstract][Full Text] [Related]
6. Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib. Krayem M; Journe F; Wiedig M; Morandini R; Sales F; Awada A; Ghanem G Eur J Cancer; 2014 May; 50(7):1310-20. PubMed ID: 24559688 [TBL] [Abstract][Full Text] [Related]
8. An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation. Heard JJ; Phung I; Potes MI; Tamanoi F BMC Cancer; 2018 Jan; 18(1):69. PubMed ID: 29320991 [TBL] [Abstract][Full Text] [Related]
9. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. Jaiswal BS; Janakiraman V; Kljavin NM; Eastham-Anderson J; Cupp JE; Liang Y; Davis DP; Hoeflich KP; Seshagiri S PLoS One; 2009 May; 4(5):e5717. PubMed ID: 19492075 [TBL] [Abstract][Full Text] [Related]
10. RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma. Dorard C; Estrada C; Barbotin C; Larcher M; Garancher A; Leloup J; Beermann F; Baccarini M; Pouponnot C; Larue L; Eychène A; Druillennec S Nat Commun; 2017 May; 8():15262. PubMed ID: 28497782 [TBL] [Abstract][Full Text] [Related]
11. SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor. Kaplan FM; Kugel CH; Dadpey N; Shao Y; Abel EV; Aplin AE J Biol Chem; 2012 Dec; 287(50):41797-807. PubMed ID: 23076151 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. Peng SB; Henry JR; Kaufman MD; Lu WP; Smith BD; Vogeti S; Rutkoski TJ; Wise S; Chun L; Zhang Y; Van Horn RD; Yin T; Zhang X; Yadav V; Chen SH; Gong X; Ma X; Webster Y; Buchanan S; Mochalkin I; Huber L; Kays L; Donoho GP; Walgren J; McCann D; Patel P; Conti I; Plowman GD; Starling JJ; Flynn DL Cancer Cell; 2015 Sep; 28(3):384-98. PubMed ID: 26343583 [TBL] [Abstract][Full Text] [Related]
13. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma. Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552 [TBL] [Abstract][Full Text] [Related]
14. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705 [TBL] [Abstract][Full Text] [Related]
15. Active Ras induces heterodimerization of cRaf and BRaf. Weber CK; Slupsky JR; Kalmes HA; Rapp UR Cancer Res; 2001 May; 61(9):3595-8. PubMed ID: 11325826 [TBL] [Abstract][Full Text] [Related]
16. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. Roskoski R Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796 [TBL] [Abstract][Full Text] [Related]
17. Constitutive activation of the ERK pathway in melanoma and skin melanocytes in Grey horses. Jiang L; Campagne C; Sundström E; Sousa P; Imran S; Seltenhammer M; Pielberg G; Olsson MJ; Egidy G; Andersson L; Golovko A BMC Cancer; 2014 Nov; 14():857. PubMed ID: 25413220 [TBL] [Abstract][Full Text] [Related]
18. A novel phosphorylation site involved in dissociating RAF kinase from the scaffolding protein 14-3-3 and disrupting RAF dimerization. Yu A; Nguyen DH; Nguyen TJ; Wang Z J Biol Chem; 2023 Oct; 299(10):105188. PubMed ID: 37625591 [TBL] [Abstract][Full Text] [Related]
19. KIT Suppresses BRAF Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418 [TBL] [Abstract][Full Text] [Related]